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ments. In addition, diabetic patients with low education level cost 2.341€ cost more 
on average in comparison to better educated patients. ConClusions: T2DM is an 
expensive to treat disease and in the era of limited resources and escalating costs 
it is critical to implement sound public health policies in order to achieve patient’s 
good glycemic control and consequently less burden to health care budgets.
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objeCtives: To calculate the cost of illness (COI) associated with adrenal insuffi-
ciency (AI) in the UK. AI patients do not produce cortisol and require glucocorticoid 
replacement therapy (RT) to survive, which is predominantly immediate-release 
hydrocortisone in the UK. With current therapy, AI patients have increased mor-
bidity and premature mortality, and suffer reduced quality-of-life. Methods: The 
COI determines the direct and indirect costs over a 1-year period. The COI includes 
the cost of RT, primary and secondary care costs (GP and outpatient appointments; 
admissions for adrenal crises; diagnosis and management of AI) and those associ-
ated with reduced productivity (absenteeism). Direct costs were estimated using 
national reference costs, Payment by Results tariffs and other published data. AI 
prevalence and adrenal crises data were taken from published literature and activity 
data (hospital admissions for management of AI) from Hospital Episode Statistics 
(HES) data. A 2012 worldwide survey of AI patients was used to determine days 
taken off work and clinical expert opinion was sought to determine total outpatient 
appointments per year. The costs associated with premature mortality, the treat-
ment and management of co-morbidities and the burden associated with reduced 
quality of life were not included due to lack of data. Results: There are ~20,000 AI 
patients in the UK. Based upon the burden of disease calculations, the estimated 
COI associated with AI is £1,922 per patient or £39.7 million over 1 year: RT, £21.7 
million; GP appointments, £1.8 million; secondary care, £4.4 million; and reduced 
productivity, £11.8 million. ConClusions: The high health care and social costs 
associated with AI highlight the clinical and economic need to improve RT. Indeed, 
as some consequences of the disease were not included in the calculations, £39.7 
million is likely a considerable underestimate of the true burden of disease.
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objeCtives: To assess the direct costs associated to type I and II diabetes mellitus 
(DM) from a health care perspective in Spain. Methods: We performed a cost of ill-
ness study considering the prevalence approach. The use of resources was estimated 
from the existing Spanish health care databases and bibliographic references. Costs 
evaluated were: hospital costs (including outpatient care), primary care costs, drugs 
costs, consumables costs and additional tests costs. All costs were updated to 2012 
euros. Results: The total direct annual cost of DM was 5,809 million euros repre-
senting 8.2% of the total Spanish health expenditure. The total drug cost accounted 
for 2,232 million euros (38%) and was mainly due to the elevated contribution of 
non-antidiabetic drugs (24%). Hospital costs represented 1,934 million € (33%) and 
were mainly driven by the acute and chronic complications (17%). Cardiovascular 
disease cost (521 million € ) and peripheral vascular disease costs (127 million € ) 
were the most important complications cost drivers. The contribution of monitoring 
strips to the total cost was only 118 million € (2%). Total complications cost repre-
sented 2,143 million € (37% of the total direct cost). ConClusions: DM total direct 
costs are strongly conditioned by DM complications cost and have a considerable 
economic impact on Spanish health expenditure. In order to reduce the health and 
economic impact generated by DM, the introduction of measures and strategies 
focused on improving the efficiency of the treatment of the disease are crucial.
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objeCtives: There have been a number of studies quantifying the direct and indi-
rect resource implications associated with severe hypoglycaemia episodes (SHE) 
and non-severe hypoglycaemia episodes (NSHE). The objective of this study was to 
calculate the total direct and indirect economic burden associated with SHE and 
NSHE in insulin treated type 2 diabetes mellitus (T2DM) subjects. Methods: We 
conducted two literature reviews of the MEDLINE database for studies published 
between June 1, 2007 and June 1, 2012. The first assessed the direct (primary and 
secondary care and treatment related) and indirect resource implications (lost pro-
ductivity) associated with SHE and NSHE; the second established the frequency of 
NSHE and SHE in insulin-based clinical trials where sulfonylurea usage was also 
reported in T2DM. An economic model written in Microsoft Excel was developed to 
predict the expected annual per-patient cost (using 2011 US costs) associated with 
the incidence of hypoglycaemia. Results: Resource utilisation from 6 studies and 
data characterising hypoglycaemia frequency were extracted from 82 studies for a 
total of 155 trial arms where the search criteria were met. Mean annual hypoglycae-
mia event rates were 16.4, 8.9, 4.8 and 2.6 for NSHE and 0.083, 0.039, 0.015 and 0.003 
for SHE associated with baseline HbA1c levels of 6%, 7%, 8% and 9% respectively.
Total expected annual per-patient hypoglycaemia costs were $929, $471, $237 and 
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objeCtives: Severe hypoglycaemias occurring in diabetes care are associated with 
a major economic burden on health care systems, with a major part of the direct 
costs resulting from the small proportion of patients who are admitted to hospital. 
We assessed the inpatients costs of severe hypoglycaemic events in Type 1 and 2 
diabetes (SHE) patients in France. Methods: The study was done using the 2012 
French National Database on hospital care (PMSI). This comprehensive database 
covers all hospital stays in the French population (over 20 million hospital stays per 
year). SHE were identified using ICD10 codes of hypoglycaemias (E160, E161, E162, 
T383) in combination with diabetes codes (E11, E10, E13, E14, N083) and excluding 
gestational diabetes. Directs costs to the health care system were estimated using 
the French National Costs study (2011 values). Results: Overall, in 2012, 17,835 
stays for diabetes related hypoglycaemias were identified in the database corre-
sponding to 16,406 patients. 8.7% of patients were hospitalized twice in the year for 
SHE, 51% were male and aged 66.7 years on average (SD 19.7). 90% of stays occurred 
in public hospitals and mean length of stay was 8.1 days (median 7.0). The mean 
direct cost of one SHE hospital stay was € 4,360. Extrapolated to the whole country 
the direct cost of hospitalized SHE was € 77.7 million which roughly correspond to 
1.2% of the overall diabetes costs for the health care system. Such value would be 
considered a conservative estimate due to potential underreporting of cases in the 
database. ConClusions: Our study confirmed that hypoglycaemic events lead to 
substantial costs for the community even it was limited to direct costs in inpatient 
setting. As the short-term and long term consequences of hypoglycaemia begin to 
be better understood, more studies have to be done to estimate the full economic 
burden of this disease.
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objeCtives: Health expenditure to treat and prevent T2DM and its complications 
was estimated at USD 345 million for OECD countries in 2010. These costs pose 
great burden to national health system’s budget, which is already under pres-
sure. In Greece there are no studies that provide information on the costs of T2DM 
patients including the cost of complications, hospitalizations and co-morbidities. 
The current study aimed to estimate the total cost of T2DM patients from a third 
party payer perspective. Methods: A retrospective research study was performed 
in four major hospital diabetes centers and 211 patients with at least 10 years 
of T2DM from diagnosis. Patients were categorized in two groups, controlled and 
uncontrolled. Hospitalization and management of complications was based on DRG 
cost. Pharmaceutical and diagnosis cost was based on official NHS prices. Health 
care cost corresponds to 2012 Euros and the perspective used was of the Social 
Security Fund. Subgroup analysis was performed in order to evaluate the cost dif-
ference between controlled vs. uncontrolled, obese non-obese and various other 
subgroups. Results: The mean age of patients was 72.9±8.1 years with mean T2DM 
duration 21.2±7.5 years, and mean HbA1c 7.3±1.0%. The mean average yearly cost of 
T2DM was € 7.111 whereas only the18.8% was attributed to cost of antidiabetic drugs. 
Controlled patients (HbA1c ≤ 7) cost on average 6.366 and uncontrolled (HbA1c> 7) 
€ 7.783. The mean hospitalization and complication cost was € 2.456. It was found 
no difference of mean hospitalization and complication cost between controlled 
and uncontrolled patients (p= 0.09). Co-morbidities cost absorbs the majority of the 
budget and was the differentiating factor between two groups. Few patients (21.8%) 
reported admission to hospital with similar hospitalization rates on number and 
duration between the two groups. ConClusions: T2DM is an expensive to treat 
disease with very high cost complications with economic and societal burden.
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objeCtives: Health expenditure to treat and prevent T2DM and its complications 
was estimated at USD 345 million for OECD countries in 2010. These costs pose a 
great burden to the national health system’s budget, which is already under pres-
sure. In Greece there are no studies that provide information on the costs of T2DM 
patients including the cost of complications, hospitalizations and co-morbidities. 
The current study aimed to estimate the total cost of T2DM patients from a third 
party payer perspective. Methods: A retrospective research study was performed 
in four major hospital diabetes centers and 211 patients with at least 10 years 
of T2DM since diagnosis. Patients were categorized in two groups, controlled and 
uncontrolled. Hospitalization and management of complications was based on DRG 
cost. Pharmaceutical and diagnosis cost was based on official NHS prices. Health 
care cost corresponds to 2012 Euros and the perspective used was of the Social 
Security Fund. Subgroup analysis was performed in order to evaluate the cost differ-
ence between controlled vs. uncontrolled, obese non-obese and various other sub-
groups. Results: The mean average yearly cost of T2DM was € 7.111 whereas only 
18.8% was attributed to cost of antidiabetic drugs. Diabetic men cost 2.222€ more per 
year in comparison to diabetic women, whereas obese diabetics cost 1.460€ more 
per year in comparison to overweight and normal patients. These may be explained 
by the higher levels of HbA1c, co-morbidities and the number of antidiabetic treat-
